LBRX

LB Pharmaceuticals Inc

Sep 16 • 04:00PM ET

15.78

-0.93 -5.57 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	22.44M	Perf Week	-
Market Cap	110.78M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	9.77%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-8.79%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	20.25 -22.07%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	-211.45% -	ROIC	-	52W Low	15.79 -0.09%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-5.21%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-5.21%	Rel Volume	0.12	Prev Close	16.71
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	-5.21%	Avg Volume	1.60M	Price	15.78
IPO	Sep 11, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	188,962	Change	-5.57%

Sep-12-25 04:27PM

Crunching the numbers on this week's IPO performances

(Yahoo Finance Video)

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	2,000,000	30,000,000	2,686,138	Sep 16 06:09 PM
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	666,666	9,999,990	666,666	Sep 16 06:09 PM
Pontifax Management 4 G.P. (20	10% Owner	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Nussbaum Ran	Director	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Vida Ventures GP III, L.L.C.	10% Owner	Sep 12 '25	Buy	15.00	333,333	4,999,995	880,214	Sep 16 03:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBRX

LB Pharmaceuticals Inc

Upgrade your FINVIZ experience